Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center

World Journal of Surgery

Volumn 36, Issue 6, 2012, Pages 1419-1431

  Norlén, Olov ^a,b   Stålberg, Peter ^a   Öberg, Kjell ^a   Eriksson, John ^a   Hedberg, Jakob ^a   Hessman, Ola ^a   Janson, Eva Tiensuu ^a   Hellman, Per ^a   Åkerström, Göran ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; INTESTINE TUMOR; LAPAROTOMY; LIVER TUMOR; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SMALL INTESTINE; SURVIVAL;

AGED; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LAPAROTOMY; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMORS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84864280270     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-011-1296-z     Document Type: Article

References (48)

1. Yao JC, Hassan M, Phan A et al (2008) One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072
2. Zar N, Garmo H, Holmberg L et al (2004) Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 28:1163-1168 (Pubitemid 40109870)
3. Makridis C, Oberg K, Juhlin C et al (1990) Surgical treatment of mid-gut carcinoid tumors. World J Surg 14:377-383 discussion 384-375
4. Åkerstrom G, Hellman P, Hessman O (2005) Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 19:717-728 (Pubitemid 41614119)
5. Pape UF, Jann H, Muller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256-265
6. Janson ET, Holmberg L, Stridsberg M et al (1997) Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8:685-690 (Pubitemid 27372168)
7. Moller JE, Pellikka PA, Bernheim AM et al (2005) Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 112:3320-3327 (Pubitemid 43739378)
8. Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89:471-476
9. Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885-894
10. Jann H, Roll S, Couvelard A et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117:3332-3341
11. Cunningham JL, Grimelius L, Sundin A et al (2007) Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol 46:747-756 (Pubitemid 47123778)
12. Akerstrom G (1989) Surgical treatment of carcinoids and endocrine pancreatic tumours. Acta Oncol 28:409-414 (Pubitemid 19166902)
13. Akerstrom G, Makridis C, Johansson H (1991) Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 30:547-553
14. Makridis C, Rastad J, Oberg K et al (1996) Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 20:900-906 discussion 907
15. Moertel CG (1987) Karnofsky Memorial Lecture. An odyssey in the land of small tumors. J Clin Oncol 5:1502-1522
16. Ohrvall U, Eriksson B, Juhlin C et al (2000) Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24:1402-1408
17. Eckhauser FE, Argenta LC, Strodel WE et al (1982) Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery 90:720
18. Knowlessar O, Law D, Sleisinger MH (1959) Malabsorption syndrome associated with metastatic carcinoids. Am J Med 27:673-677
19. Anthony P, Drury R (1970) Elastic vascular sclerosis of mesenteric blood vessels in argentaffin carcinoma. J Clin Pathol 23:110
20. Moertel CG, Sauer WG, Dockerty MB et al (1961) Life history of the carcinoid tumor of the small intestine. Cancer 14:901-912
21. Ahlman H, Wangberg B, Jansson S et al (1991) Management of disseminated midgut carcinoid tumours. Digestion 49:78-96
22. Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776-783 discussion 783-775
23. Que FG, Sarmiento JM, Nagorney DM (2006) Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol 574:43-56
24. Wangberg B, Westberg G, TylenUet al (1996) Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 20:892-899 discussion 899 (Pubitemid 26281920)
25. Eriksson J, Stalberg P, Nilsson A et al (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32:930-938
26. Steinmuller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47-62 (Pubitemid 350308294)
27. Arnold R, Müller H, Schade-Brittinger C et al (2009) Placebocontrolled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27:15s:(suppl; abstr 4508)
28. Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757-762 (Pubitemid 47497934)
29. Åkerström G, Hellman P, Hessman O (2009) Gastrointestinal carcinoids. In: Lennard T (ed) Endocrine surgery, 4th edn. Saunders Elsevier, London, pp 147-176
30. Oberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3:863-877 (Pubitemid 37540543)
31. Janson ET, Ronnblom L, Ahlstrom H et al (1992) Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3:635-638
32. Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101-121
33. Team RDC (2007) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0; URL http://www.r-project.org/
34. Dickman PW, Sloggett A, Hills M et al (2004) Regression models for relative survival. Stat Med 23:51-64 (Pubitemid 38072106)
35. Modlin IM, Champaneria MC, Chan AK et al (2007) A threedecade analysis of 3, 911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 102:1464-1473 (Pubitemid 46976277)
36. Talback M, Rosen M, Stenbeck M et al (2004) Cancer patient survival in Sweden at the beginning of the third millennium - predictions using period analysis. Cancer Causes Control 15:967-976 (Pubitemid 39663873)
37. Tomassetti P, Campana D, Piscitelli L et al (2006) Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology 83:380-386 (Pubitemid 44729795)
38. Burke AP, Thomas RM, Elsayed AM et al (1997) Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 79:1086-1093 (Pubitemid 27118204)
39. Makridis C, Ekbom A, Bring J et al (1997) Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 122:1075-1082 (Pubitemid 28016675)
40. Elias D, Sideris L, Liberale G et al (2005) Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 137:411-416 (Pubitemid 40432038)
41. Vasseur B, Cadiot G, Zins M et al (1996) Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer 78:1686-1692 (Pubitemid 26330896)
42. Lombard-Bohas C, Mitry E, O'Toole D, FFCD-ANGH-GERCOR (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89(2):217-222
43. Hellman P, Lundstrom T, Ohrvall U et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26:991-997 (Pubitemid 36920298)
44. Soreide JA, van Heerden JA, Thompson GB et al (2000) Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg 24:1431-1436
45. Ahlman H (1996) The role of surgery in patients with advanced midgut carcinoid tumours. Digestion 57(Suppl 1):86-87 (Pubitemid 26183931)
46. Oberg K (2000) Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62(Suppl 1):92-97 (Pubitemid 30665946)
47. Faiss S, Pape UF, Bohmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689-2696 (Pubitemid 46606312)
48. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130